Skip to main content Accessibility help
×
Home
Hostname: page-component-684bc48f8b-l9xz9 Total loading time: 0.336 Render date: 2021-04-13T00:36:52.099Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants

Published online by Cambridge University Press:  07 November 2014

Abstract

Introduction: Effective management of major depressive disorder (MDD) continues to be a challenging task for psychiatrists and primary care physicians. This trial evaluated the efficacy and safety of adjunctive aripiprazole versus antidepressant monotherapy in patients with MDD and independently replicated the positive findings of two similar trials.

Methods: Patients (N=1, 147) with MDD experiencing a major depressive episode and a history of inadequate response to antidepressant monotherapy were enrolled (week 0); 827 received single-blind adjunctive placebo plus open-label antidepressant (escitalopram, fluoxetine, paroxetine controlled release, sertraline, or venlafaxine extended release) for 8 weeks to confirm inadequate response to antidepressants; 349 patients with inadequate response were randomized (1:1) to double-blind, adjunctive placebo (n=172) or adjunctive aripiprazole (n=177; 2–20 mg/day). Primary outcome was the mean change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total score from baseline (week 8) to endpoint (week 14).

Results: Clinically significant improvements in depressive symptoms as assessed by decreases in the MADRS Total score were greater with adjunctive aripiprazole (−10.1) than placebo (−6.4; P<.001). Remission rates were greater for adjunctive aripiprazole than for adjunctive placebo (week 14, 36.8% vs 18.9%; P<.001). Completion rates with adjunctive aripiprazole and placebo were high (83% vs. 87%) and discontinuations due to adverse events were low (6.2% vs 1.7%).

Conclusion: For some patients with MDD who do not obtain adequate symptom relief with antidepressant monotherapy, adjunctive therapies can significantly improve depressive symptoms. As reported, adjunctive aripiprazole was associated with a two-fold higher remission rate than adjunctive placebo. This, and previous studies, have shown that discontinuations due to adverse events were low and completion rates were high, and has indicated that both antidepressant and aripiprazole in combination were relatively well-tolerated and safe. This is the third consecutive clinical trial, in the absence of a failed trial, to demonstrate that aripiprazole augmentation to antidepressants is an efficacious and well-tolerated treatment for patients with MDD who do not respond adequately to standard antidepressant monotherapy (ClinicalTrials.gov study NCT00105196).

Type
Original Research
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below.

References

1.Murray, CJ, Lopez, AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:14981504.CrossRefGoogle ScholarPubMed
2.Kessler, RC, Berglund, P, Demler, O, et al.The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:30953105.CrossRefGoogle Scholar
3.Moussavi, S, Chatterji, S, Verdes, E, Tandon, A, Patel, V, Ustun, B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851858.CrossRefGoogle ScholarPubMed
4.Regier, DA, Narrow, WE, Rae, DS, Manderscheid, RW, Locke, BZ, Goodwin, FK. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:8594.CrossRefGoogle Scholar
5.Greenberg, PE, Birnbaum, HG, Leong, SA. Cost of depression: current assessment and future direction. Expert Review of Pharmacoeconomics & Outcomes Research. 2001;1:6976.CrossRefGoogle Scholar
6.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:2840.CrossRefGoogle ScholarPubMed
7.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al.Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163:19051917.CrossRefGoogle ScholarPubMed
8.Gaynes, BN, Rush, AJ, Trivedi, MH, et al.Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med. 2008;23:551560.CrossRefGoogle ScholarPubMed
9.Berman, RM, Marcus, RN, Swanink, R, et al.The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:843853.CrossRefGoogle ScholarPubMed
10.Marcus, RN, McQuade, RD, Carson, WH, et al.The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008;28:156165.CrossRefGoogle ScholarPubMed
11.Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.Google ScholarPubMed
12.Fava, M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649659.CrossRefGoogle ScholarPubMed
13.Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382389.CrossRefGoogle ScholarPubMed
14.Leon, AC, Shear, MK, Portera, L, Klerman, GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol. 1992;27:7882.CrossRefGoogle ScholarPubMed
15.Guy, W. Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Publication (ADM) 76-338. National Institute of Mental Health; 1976:218222.Google Scholar
16.Rush, AJ, Gullion, CM, Basco, MR, Jarrett, RB, Trivedi, MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26:477486.CrossRefGoogle ScholarPubMed
17.Rush, A, Trivedi, M, Ibrahim, HM. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573583.CrossRefGoogle ScholarPubMed
18.Endicott, J, Nee, J, Harrison, W, Blumenthal, R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321326.Google ScholarPubMed
19.Einarson, TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol. 2004;19:305310.CrossRefGoogle ScholarPubMed
20.Gorwood, P, Weiller, E, Lemming, O, Katona, C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry. 2007;15:581593.CrossRefGoogle ScholarPubMed
21.Mittmann, N, Mitter, S, Borden, EK, Herrmann, N, Naranjo, CA, Shear, NH. Montgomery-Asberg severity gradations. Am J Psychiatry. 1997;154:13201321.Google ScholarPubMed
22.Simpson, GM, Angus, JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:1119.CrossRefGoogle ScholarPubMed
23.Guy, W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health, Education, and Welfare publication (ADM) 76-338. National Institute of Mental Health; 1976:534537.Google Scholar
24.Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672676.CrossRefGoogle ScholarPubMed
25.Labbate, LA, Lare, SB. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom. 2001;70:221225.CrossRefGoogle ScholarPubMed
26.Mojtabai, R. Increase in antidepressant medication in the US adult population between 1990 and 2003. Psychother Psychosom. 2008;77:8392.CrossRefGoogle ScholarPubMed
27.Trivedi, MH, Fava, M, Wisniewski, SR, et al.Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:12431252.CrossRefGoogle Scholar
28.Trivedi, MH, Rush, AJ, Gaynes, BN, et al.Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology. 2007;32:24792489.CrossRefGoogle ScholarPubMed
29.Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358:252260.CrossRefGoogle ScholarPubMed
30.Fava, M, Evins, AE, Dorer, DJ, Schoenfeld, DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115127.CrossRefGoogle Scholar
31.Corruble, E, Legrand, JM, Zvenigorowski, H, Duret, C, Guelfi, JD. Concordance between self-report and clinician's assessment of depression. J Psychiatr Res. 1999;33:457465.CrossRefGoogle ScholarPubMed

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 186 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 13th April 2021. This data will be updated every 24 hours.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *